Intermediate compounds for the synthesis of benzimidazole derivatives and method of production thereof

 

The invention relates to new compounds of formula (1) or their pharmaceutically acceptable salts, where R1a, R2a, R3aand R4arepresent, each independently, hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, benzyloxy, acetoxy, trifluoromethyl or halogen, and R5aand R6arepresent, each independently, tert-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzenesulfonyl or p-bromobenzyloxycarbonyl, which is an intermediate compound for the synthesis of benzimidazole derivatives and their pharmaceutically acceptable salts exhibiting excellent hypoglycemic effect. The invention also relates to a method for obtaining compounds of formula (5) or its pharmaceutically acceptable salts, where R1d, R2d, R3dand R4drepresent, each independently, hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, benzyloxy, acetoxy, trifluoromethyl or halogen, and each R5dand R6drepresents tert-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzenesulfonyl or p-bromobenzyloxycarbonyl, the interaction of the compound (4) with the alkoxide of an alkali metal. 9 C.p. f-crystals, 13 PL.

Claims

1. The compound of formula (1) or its pharmaceutically acceptable salt

where R1a, R2a, R3aand R4arepresent, each independently, hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, benzyloxy, acetoxy, trifluoromethyl or halogen;

R5aand R6arepresent, each independently, tert-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzenesulfonyl or p-bromobenzyloxycarbonyl.

2. The compound or its pharmaceutically acceptable salt p. 1, where R5aand R6arepresent, each independently, tert-butoxycarbonyl.

3. The compound or its pharmaceutically acceptable salt under item 1 or 2, where R1a, R2a, R3aand R4arepresent, each independently, hydrogen or C1-C4alkoxy.

4. The compound or its pharmaceutically acceptable salt under item 1 or 2, where R1a, R2aR3aand R4arepresent, each independently, hydrogen or methoxy.

5. The compound or its pharmaceutically acceptable salt p. 1, where each of R1a, R2aand R4ais hydrogen, R3ais methoxy, and each IO pharmaceutically acceptable salt

interaction of the compound (4) with an alkali metal alkoxide

where R1d, R2d, R3dand R4drepresent, each independently, hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, benzyloxy, acetoxy, trifluoromethyl or halogen;

each of R5dand R6drepresents tert-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzenesulfonyl or p-bromobenzyloxycarbonyl.

7. The method of obtaining the compound or its pharmaceutically acceptable salt according to p. 6, where each of R5dand6drepresents tert-butoxycarbonyl.

8. The method of obtaining the compound or its pharmaceutically acceptable salt under item 6 or 7, where R1d, R2d, R3dand R4drepresent, each independently, hydrogen or C1-C4alkoxy.

9. The method of obtaining the compound or its pharmaceutically acceptable salt under item 6 or 7, where R1d, R2d, R3dand R4drepresent, each independently, hydrogen or methoxy.

10. The method of obtaining the compound or its pharmaceutically acceptable salt according to p. 6, where R1d, R2dand R4drepresent hydrogen, R3dis methoxy and each

 

Same patents:

The invention relates to new derivatives of 5-phenoxyethyl-2,4-preparations of thiazolidinediones General formula I, where a is unbranched or branched C2-C16-alkylenes group, which is saturated and optionally substituted by hydroxy or phenyl; D is a mono - or decillions aromatic group which may contain one or two oxygen atom; X denotes hydrogen, C1-C6-alkyl, alkoxyalkyl group, halogen, cyano, carboxy; n is an integer from 1-3; with the proviso that if a represents a butylene,is not 4-chloraniline group; in free form or in the form of pharmacologically acceptable salts

The invention relates to new derivatives of asola General formula I, where R1and R2the same or different, each represents hydrogen, cycloalkyl and so forth, or R1and R2forming (a) a condensed ring, (b) or (C), which may be optionally substituted substituted lower alkyl, amino group and the like; R3, R6, R7, R8the same or different, each represents a hydrogen atom, and so on; R4represents a cyano, tetrazolyl, -COOR9and so on; R5represents a hydrogen atom or lower alkyl; D represents optionally substituted lower alkylene; X and Z are the same or different, each represents oxygen or sulfur, Y is-N= or-CH=; A is-B is-O-, -S-B-, -B-S - or-In-; represents the lowest alkylene or lower albaniles; n = 2

The invention relates to a new above-mentioned compounds, method of their production and the means of containing this compound, useful for combating fungi and insect pests

The invention relates to oxime derivative of formula I, where R1- H, C1-6-alkyl, R2- C2-6-alkylene, X - C6-10-aryl unsubstituted or substituted by 1 Deputy selected from the group comprising C1-6-alkyl, HE, alloctype, C1-4-alkoxygroup, halogen atoms, phenyl, phenylthiourea, phenylsulfonyl group, phenylcarbonylamino, pyridylsulfonyl group, imidazolidine and peredelnye group or heteroaromatic group: pyridyl, chinosol and imidazolyl ; Y = O, S, orZ represents a group of the formula (For), (Zв ), (Zс ) or ( Zd )

The invention relates to new preparations of thiazolidinediones of the formula I, where A denotes a carbocyclic ring with 5 or 6 carbon atoms or a heterocyclic aromatic 5-or 6-membered ring containing an S atom or N; B is-CH=CH-; W represents O; X represents O; Y represents N; R represents pyridyl, thienyl or phenyl, in case you need one - or disubstituted C1-C3-alkyl, CF3, Cl or bromine; R1represents C1-C6-alkyl;n represents 2, and their tautomers, enantiomers, diastereomers or physiologically acceptable salts and medicinal product on the basis of their

The invention relates to a number of derivatives of thiazolidine, which are characterized by the presence of quinone group 2 in their molecules

The invention relates to a number of derivatives of thiazolidine, characterized by the presence along with other hydroxynonenal group or naphthohydroquinone groups in their molecules

The invention relates to two intermediate compounds that are useful for a number of compounds characterized 2-[2-/replaced phenyloxy-, thio - or-methyl/-1-methyl-ethyl]-aminoethanol structure and possess valuable anti-diabetic properties, which means struggle with weight

The invention relates to a method for producing 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl] methoxy] benzyl] thiazolidin-2,4-dione of formula (1), including the restoration of the compounds of formula (2'), where R is a (C1-C4)alkyl group, with the use of Raney Nickel or magnesium and, optionally, re-esterification using sulfuric acid in the temperature range from 0 to 60oWith obtaining the compounds of formula (3'), which is subjected to hydrolysis to obtain the acid of formula (4), the condensation of the acid of formula (4) with N-methyl-anthranilamide formula (7) without any pre-activation of the acid to obtain the compounds of formula (1), which is optionally transformed into a pharmaceutically acceptable salt

The invention relates to new derivatives of vitamin D General formula I

< / BR>
where Y1- OH, C1-12alkanoyloxy or optionally substituted benzoyloxy, Y2- H, C1-12alkanoyl or optionally substituted benzoline group, R1and R2together ekzoticheskaya methylene group, R3and R4independently - H, C1-4alkyl, Q - C1-3alkylen, possibly substituted inoris HE in the group, which, in turn, can be etherification, R5and R6at the same time C1-4alkyl, or R5and R6together with carbon atom C-25 form cyclopropyl group, Z is a 5-6-membered aromatic Carbo - or heterocycle, such as phenyl, oxazole, thiazole, furan, thiophene, pyrrole, isoxazol, pyrazole, triazole, pyridine, pyrimidine, possibly substituted C1-12alkylen

The invention relates to new derivatives of vitamin D General formula I

< / BR>
where Y1- OH, C1-12alkanoyloxy or optionally substituted benzoyloxy, Y2- H, C1-12alkanoyl or optionally substituted benzoline group, R1and R2together ekzoticheskaya methylene group, R3and R4independently - H, C1-4alkyl, Q - C1-3alkylen, possibly substituted inoris HE in the group, which, in turn, can be etherification, R5and R6at the same time C1-4alkyl, or R5and R6together with carbon atom C-25 form cyclopropyl group, Z is a 5-6-membered aromatic Carbo - or heterocycle, such as phenyl, oxazole, thiazole, furan, thiophene, pyrrole, isoxazol, pyrazole, triazole, pyridine, pyrimidine, possibly substituted C1-12alkylen

The invention relates to a method for producing derivatives of 1,4-dihydropyridines F.-ly (I), where R1is hydrogen; R2, R3and R5denote (C1-C5)alkoxy-C(= O)-; R4is phenyl or substituted by halogen phenyl, R6- heterocyclic ring containing up to 2 heteroatoms selected from sulfur and nitrogen; Y is methylene

The invention relates to the chemical industry, in particular the production of the accelerator of vulcanization of the rubber mixtures for the production of technical rubber, asbestos technical products and products tire industry

The invention relates to carbamoyloximes General formula I

< / BR>
where R1selected from the group comprising alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl and substituted heteroaryl; R2represents alkyl, and R1and R2together with the nitrogen atom associated with R2and SO2the group associated with R1may form a heterocyclic or substituted heterocyclic group; R3represents hydrogen, and when R2does not form a heterocyclic group with R1then R2and R3together with the nitrogen atom associated with R2and the carbon atom bound to R3may form a heterocyclic or substituted heterocyclic group; R5represents -(CH2)x-Ar-R5'where R5'selected from the group comprising-O-Z-NR8R8'and-O-Z-R12where R8and R8'independently selected from the group comprising hydrogen, alkyl, substituted alkyl, heterocyclyl, and where R8and R8'combined with the formation of the heterocycle or substituted heterocycle, R12selected from the group comprising heterocycle substituted heteroaryl, x is an integer from 1 to 4; Q represents-C(X)NR7- where R7represents hydrogen, and X represents oxygen; and its pharmaceutically acceptable salts; the compounds of formula IA, where instead of the hydroxyl group on the C-end - radical R6that represents alkoxy, substituted alkoxy, cycloalkane, or-NH-substituted; two pharmaceutical compositions, having the ability to block or inhibit cell adhesion, containing as active ingredient a compound I or compound IA; method binding VLA-4 in a biological sample, and the method of treating inflammatory conditions in a patient is a mammal

The invention relates to a method for producing acid salt of (Z)-2-aminothiazole the compounds of formula (I), where R1and R2independently represent an alkyl group having 1-5 carbon atoms, Y represents a halogen atom, m represents the valency of the inorganic acid of the formula (III) and n represents the integer 1 or 2, including the interaction of the acid salt of 2-aminothiazoline the compounds of formula (II), where R1and R2independently represent an alkyl group having 1-5 carbon atoms, X represents a bromine atom or an iodine atom and the wavy line indicates that this compound is a mixture of E - and Z-isomers, with an inorganic acid of the formula HY (III), where Y represents a halogen atom, and where the acid salt of 2-aminothiazoline the compounds of formula (II) is a compound obtained by the interaction of thiourea and halogenated compounds of the formula (VI), where R1, R2X and the wavy line have the same meanings as defined above

The invention relates to new thiazole derivative of the formula (I) in which R1denotes a group of formula (a)-(d), where R2denotes a group of formula (II), R3denotes hydrogen, alkyl, cycloalkyl, and so on; R4denotes alkyl, phenyl, heteroaryl; R5and R6each independently of one another denote hydrogen, heteroaryl; R7and R8each independently of one another denotes hydrogen, or R7and R8together with the N atoms to which they are linked, form a 5-6-membered heterocycle; R9denotes hydrogen, alkyl, cycloalkyl; R10denotes phenyl, benzyl, and so on; And denotes a carbonyl or sulfonyl; In denotes hydrogen; and m each represents zero or a positive number from zero to 2, but not equal to zero when R1denotes-NH2; b denotes a number from zero to 4; C, d, f, g, k, l and m each independently of one another denotes zero or 1, so that each of the C, f and g cannot simultaneously denote zero and thus m does not denote zero when f or g represents 1; q represents zero or 1, and each k and l also denotes zero, when i denotes zero; e denotes a number from zero to 3; h represents a number from zero to 5; j denotes a number from zero to 2; and the sum is

The invention relates to a method of obtaining thiazolidine and its salts by reacting hexamethylenetetramine formula (I) with applied or its salts of the formula (II), where X(-)represents an acid residue in a polar solvent

The invention relates to novel polycyclic to dihydrothiazolo General formula (I), where Y is a simple bond; X is CH2; R1 is H, F, Cl, NO2, CN, COOH, (C1-C6)-alkyl, (C2-C6)-quinil, O-(C1-C6)-alkyl, and alkyl residues one, several or all of the hydrogen atoms may be replaced by fluorine; (CH2)n-phenyl, SO2-(C1-C6)-alkyl, and n = 0 and the phenyl residue up to twice may be substituted by F, Cl, CF3, OCF3, O-(C1-C6)-alkyl, (C1-C6)-alkyl; O-(CH2)n-phenyl, and n = 0 and phenyl cycle can be one - to twofold substituted by Cl, (C1-C6)-alkyl; 1 - or 2-naphthyl, 2 - or 3-thienyl; R1' is hydrogen; R2 is H, (C1-C6)-alkyl, R3 is hydrogen; R4 - (C1-C8)-alkyl, (C3-C7-cycloalkyl, (CH2)n-aryl, and n = 0-1, and aryl can be phenyl, 2-, 3 - or 4-pyridyl, 2 - or 3-thienyl, 2 - or 3-furyl, indol-3-yl, indol-5-yl, and aryl or heteroaryl residue up to twice may be substituted by F, Cl, HE, OCF3, O-(C1-C6)-alkyl, (C1-C6)-alkyl, 2-, 3-, 4-pyridium, pyrrol-1-yl, with peregrinae ring may be substituted CF3; and their physio is

The invention relates to the use as a medicinal substance medications for the treatment of diseases associated with impaired venous function and/or inflammatory edema tricyclic derivatives of 1,4-dihydro-1,4-dioxo-1H-naphthalene and its new compounds of General formula I, where a is either a sulfur atom, oxygen or the radical R3N, where R3is a hydrogen atom, a C1-C5-alkyl; R1is either1-C5-alkyl, or phenyl ring, unsubstituted or substituted by one or more groups selected from methyl, methoxy, fluorine, chlorine, or 5-6-membered heteroaromatic ring having one or more heteroatoms selected from oxygen, sulfur, nitrogen, unsubstituted or substituted group selected from chlorine, bromine, nitro, amino, acetamido, acetoxymethyl, methyl, phenyl; R2is a hydrogen atom, halogen, C1-C5-alkyl, hydroxy, and methoxy; and pharmaceutically acceptable salts
Up!